IL1A and Encephalopathy: Compared with the anti-IL-6 receptor antibody tocilizumab, the current first-line therapy for CAR T-induced CRS fails to prevent CAR T-induced encephalopathy, one advantage of using IL-1 blockade is to reduce systemic concentrations of IL-1 that can cross the blood-brain barrier and cause neurotoxicity [37].